{"id":"mk0733-duration-of-treatment-18-weeks","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL3923410","moleculeType":"Small molecule","molecularWeight":"491.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug works by binding to and blocking NK1 receptors, which are involved in pain transmission and emetic (nausea/vomiting) pathways. By antagonizing these receptors, MK0733 may reduce pain perception and chemotherapy-induced nausea and vomiting (CINV). This mechanism has been explored in various pain and antiemetic indications.","oneSentence":"MK0733 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:21:40.870Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV)"},{"name":"Postoperative nausea and vomiting (PONV)"}]},"trialDetails":[{"nctId":"NCT00389896","phase":"PHASE3","title":"A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-07-26","conditions":"HDL Cholesterol","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK0733 / Duration of Treatment: 18 Weeks","genericName":"MK0733 / Duration of Treatment: 18 Weeks","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK0733 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}